|
MechanismCTLA4 inhibitors |
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评估IBI310 联合信迪利单抗新辅助治疗可切除的高度微卫星不稳定型(MSI-H)或错配修复缺陷型(dMMR)结肠癌的有效性和安全性的Ib/III 期研究
[Translation] A phase Ib/III study to evaluate the efficacy and safety of IBI310 combined with sintilimab in the neoadjuvant treatment of resectable microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colon cancer
评估IBI310 联合信迪利单抗在 MSI-H/dMMR 结肠癌受试者中的疗效和安全性。
[Translation] To evaluate the efficacy and safety of IBI310 combined with sintilimab in subjects with MSI-H/dMMR colon cancer.
IBI310(抗-CTLA-4)联合信迪利单抗用于标准治疗后进展的晚期胆道癌的单臂、多中心、Ib/II期研究
[Translation] A single-arm, multicenter, phase Ib/II study of IBI310 (anti-CTLA-4) combined with sintilimab for advanced biliary tract cancer that has progressed after standard therapy
评价IBI310联合信迪利单抗在既往接受过至少1线标准治疗后进展的晚期胆道癌患者中的疗效
[Translation] To evaluate the efficacy of IBI310 combined with sintilimab in patients with advanced biliary tract cancer who have progressed after at least 1 line of standard treatment
IBI310(抗CTLA-4)联合信迪利单抗治疗晚期或转移性非小细胞肺癌的开放、多中心、Ib期研究
[Translation] An open, multicenter, phase Ib study of IBI310 (anti-CTLA-4) combined with sintilimab in the treatment of advanced or metastatic non-small cell lung cancer
主要目的:
评价IBI310联合信迪利单抗治疗晚期或转移性非小细胞肺癌(Non-Small Cell Lung Cancer, NSCLC)的安全性和疗效。
次要目的:
1.评价IBI310联合信迪利单抗治疗晚期或转移性NSCLC的健康状况和生活质量;
2.评价IBI310联合信迪利单抗治疗晚期或转移性NSCLC的群体药代动力学特征。
[Translation] Primary objective:
To evaluate the safety and efficacy of IBI310 combined with sintilimab in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC).
Secondary objectives:
1. To evaluate the health status and quality of life of IBI310 combined with sintilimab in the treatment of advanced or metastatic NSCLC;
2. To evaluate the population pharmacokinetic characteristics of IBI310 combined with sintilimab in the treatment of advanced or metastatic NSCLC.
100 Clinical Results associated with Suzhou Xinda Biotechnology Co., Ltd.
0 Patents (Medical) associated with Suzhou Xinda Biotechnology Co., Ltd.
100 Deals associated with Suzhou Xinda Biotechnology Co., Ltd.
100 Translational Medicine associated with Suzhou Xinda Biotechnology Co., Ltd.